Recidiv x Šele - Bolest
Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast Cancer
Recidiv - Slalom
Revumenib vs. Ziftomenib: Which One to Pick of the Two Choices for Relapsed/Refractory AML?
Recidiv x High Fresh - Lice U Lice
Segment 4- Impact of Major Trials on CLL Treatment
Maintenance/Consolidation Therapy in NSCLC
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
OsteoBites: Domatinostat/Sirolimus Sarcoma Trial (Relapsed/Refractory Phase 1/2)
Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM
Treatment After Progression in Follicular Lymphoma
Results from MonumenTAL-1: First-in-Human Study of Talquetamab in Pts with RR Multiple Myeloma
KOMET-001 Study Design: Which Led to the FDA approval of Ziftomenib in NPM1-Mutated AML
How to Treat Adjuvant or Metastatic Kidney Cancer?
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Geoffrey L. Uy, MD: Investigating Flotetuzumab in AML and MDS
Screening for clinical variables to predict late distance disease recurrence
Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MS
Resistance to acalabrutinib in CLL is mediated by BTK mutations
Risk of Early Versus Late Recurrence
